Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07549919

A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants

This is a Phase 1, randomized, single-dose, open-label, two-way crossover study to evaluate the effect of food on AJ201, and to evaluate the safety, tolerability, and pharmacokinetics of AJ201 in Japanese and White healthy male participants.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

AnnJi Investigational Site

Los Alamitos, California, 90720, United States

Location status: Recruiting

Location contact

CNS Outreach

CONTACT

[email protected]

844-424-9494

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Male, non-smokers (no use of tobacco or nicotine products within 3 months prior to Screening), ≥ 18 and ≤ 55 years of age, with body mass index (BMI) ≥ 18.5 and ≤ 30.0 kg/m2 and body weight ≥ 50.0 kg.
  • Normal renal function at Screening.
  • Healthy as defined by:
  • The absence of clinically significant illness and surgery within 4 weeks prior to study drug administration.
  • The absence of a clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, depression, attempted suicide, gastrointestinal, renal, hepatic, and metabolic disease.
  • Participants must be either Japanese or White.
  • Able to understand the study procedures and provide signed informed consent to participate in the study.

Key Exclusion Criteria:

  • Any clinically significant abnormal finding at physical examination.
  • Clinically significant abnormal laboratory test results or positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen and antibody, at Screening.
  • Positive urine drug screen, urine cotinine test, or alcohol breath test.
  • History of significant allergic reactions to any drug.
  • Clinically significant ECG abnormalities or vital signs abnormalities at Screening.
  • History of drug abuse of any soft drugs or hard drugs.
  • History of alcohol abuse.
  • History of smoking or uses other nicotine-containing products.
  • Undergone major surgery ≤ 3 months before first study drug administration.
  • History of clinically significant opportunistic infection or serious local infection or significant medical/surgical procedure or trauma or any current infection.
  • Use of medications for the timeframes specified in the protocol.
  • Presence of orthodontic braces or orthodontic retention wires, or any physical findings in the mouth or tongue that would interfere with the dosing procedure.

Treatment and study plan

AJ201

Drug

All participants are planned to be administered a single dose of AJ201 for each period (fed and fasted).

Primary outcomes

  1. Plasma PK of AJ201

    Time frame: Pre-dose to Day 6

    AUC0-24hr: Area under the concentration-time curve from zero to 24 hours under fasting and fed conditions

  2. Plasma PK of AJ201

    Time frame: Pre-dose to Day 6

    AUC0-last: Area under the concentration-time curve from zero to the last observed concentration under fasting and fed conditions

  3. Plasma PK of AJ201

    Time frame: Pre-dose to Day 6

    AUC0-inf: Area under the concentration-time curve from time zero to infinity (extrapolated) under fasting and fed conditions

  4. Plasma PK of AJ201

    Time frame: Pre-dose to Day 6

    Cmax: Maximal observed concentration under fasting and fed conditions

  5. Plasma PK of AJ201

    Time frame: Pre-dose to Day 6

    Tmax: Time when the maximal concentration is observed under fasting and fed conditions

  6. Plasma PK of AJ201

    Time frame: Pre-dose to Day 6

    Residual area: Percentage of AUC0-inf due to extrapolation from the time of the last observed concentration to infinity, calculated as

    [1 - (AUC0-last/AUC0-inf)] x 100 under fasting and fed conditions

  7. Plasma PK of AJ201

    Time frame: Pre-dose to Day 6

    Tlag: Time of observation prior to the first observation with a measurable (non-zero) concentration under fasting and fed conditions

  8. Plasma PK of AJ201

    Time frame: Pre-dose to Day 6

    T½ el: Terminal elimination half-life under fasting and fed conditions

  9. Plasma PK of AJ201

    Time frame: Pre-dose to Day 6

    Kel: Terminal elimination rate constant under fasting and fed conditions

  10. Plasma PK of AJ201

    Time frame: Pre-dose to Day 6

    Cl/F: Apparent clearance under fasting and fed conditions

  11. Plasma PK of AJ201

    Time frame: Pre-dose to Day 6

    Vz/F: Apparent volume of distribution under fasting and fed conditions

  12. Urine PK of AJ201

    Time frame: Pre-dose to Day 7

    Ae0-24hr: Cumulative urinary excretion from time zero to 24 hours, calculated as the sum of the amounts excreted over each collection interval under fasting and fed conditions

  13. Urine PK of AJ201

    Time frame: Pre-dose to Day 7

    Ae0-48hr: Cumulative urinary excretion from time zero to 48 hours, calculated as the sum of the amounts excreted over each collection interval under fasting and fed conditions

  14. Urine PK of AJ201

    Time frame: Pre-dose to Day 7

    Ae0-last: Cumulative urinary excretion from time zero to the last observed concentrations, calculated as the sum of the amounts excreted over each collection interval under fasting and fed conditions

  15. Urine PK of AJ201

    Time frame: Pre-dose to Day 7

    Rmax: Maximal rate of urinary excretion, calculated by dividing the amount of drug excreted in each collection interval by the time over which it was collected under fasting and fed conditions

  16. Urine PK of AJ201

    Time frame: Pre-dose to Day 7

    TRmax: Time of maximal urinary excretion, calculated as the midpoint of the collection interval during which Rmax occurred under fasting and fed conditions

  17. Urine PK of AJ201

    Time frame: Pre-dose to Day 7

    ClR: Renal clearance, calculated as Ae0-24hr /AUC0-24hr under fasting and fed conditions

Secondary outcomes

  1. Safety and Tolerability of AJ201

    Time frame: Baseline to Day 12

    Incidence and proportion of volunteers with AEs, including TEAEs and SAEs

Study contacts

Contact information is provided by the study sponsor or research team.

Andy Chen, PhD

CONTACT

[email protected]

+886223655677 ext. 801

Sponsors and collaborators

Lead sponsor

AnnJi Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Phase 1, Randomized, Single-dose, Open-label, Two-way, Crossover Study to Evaluate the Effect of Food on AJ201, and to Evaluate the Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 24, 2026
Registry last updated
Apr 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.